Founded in 2013, Syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal Fc receptor (FcRn). The company is developing SYNT001, a biologic that blocks the FcRn-IgG interaction for the treatment of IgG-mediated autoimmune diseases.